G9a, a histone methyltransferase, has been identified as a potential therapeutic target, with its inhibition in HB cell lines and animal models demonstrating significant antitumor effects, providing hope for improved treatment outcomes. This evidence concerns the gene PRDM9 and hemoglobin measurement.